Ticker,Title,Link
BBIO,BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA...,8/29/2024 1:30:00 PM
BBIO,BridgeBio Pharma to Participate in September Investor Events,8/28/2024 1:30:00 PM
BBIO,BridgeBio Pharma: Strategic Collaborations and Promising Pipeline Bolster Buy Rating,8/27/2024 10:15:44 AM
BBIO,BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal...,8/26/2024 1:30:00 PM
BBIO,Positive Buy Rating for BridgeBio Pharma Backed by Strategic Initiatives and Upcoming Catalysts,8/22/2024 10:17:40 AM
BBIO,BridgeBio forms joint venture GondolaBio for rare disease assets,8/21/2024 4:59:22 PM
BBIO,"BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia",8/19/2024 1:30:00 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),8/8/2024 1:30:00 PM
BBIO,Evercore ISI Sticks to Their Buy Rating for BridgeBio Pharma (BBIO),8/7/2024 12:14:20 PM
BBIO,Buy Rating Affirmed on BridgeBio Pharma’s Promising Pipeline and Regulatory Prospects,8/5/2024 10:29:16 AM
BBIO,Bank of America Securities Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO),8/2/2024 1:47:40 PM
BBIO,Buy Rating on BridgeBio Pharma: Promising Clinical Trials and Potential Market Dominance for Acoramidis,8/1/2024 9:35:44 PM
BBIO,"BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer",7/23/2024 1:30:00 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),7/5/2024 10:31:00 PM
BBIO,Buy Rating Affirmed for BridgeBio Pharma Amid Market Overreaction and Promising Long-Term Prospects,7/1/2024 10:09:10 AM
BBIO,Maintaining Buy Rating on BridgeBio Pharma Amidst Competitive Dynamics and Market Undervaluation,6/25/2024 9:58:27 AM
BBIO,Buy Rating Affirmed for BridgeBio Pharma Amid Market Overreaction to Competitor’s Study,6/24/2024 6:05:21 PM
BBIO,TD Cowen Keeps Their Buy Rating on BridgeBio Pharma (BBIO),6/21/2024 11:25:22 AM
BBIO,Analyst Issues Buy Rating for BridgeBio Pharma on Strong Clinical and Regulatory Prospects,6/20/2024 10:37:32 AM
BBIO,BridgeBio's BBP-418 Gets FDA Rare Pediatric Disease Designation For Treatment Of LGMD2I/R9 ,6/18/2024 2:45:15 PM
BBIO,Buy Rating Affirmed on BridgeBio Pharma with High Hopes for Acoramidis and Expanding ATTR-CM Market,6/13/2024 9:56:54 AM
BBIO,Citi opens upside catalyst watch on Alnylam ahead of ATTR-CM data,6/12/2024 2:55:44 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),6/10/2024 1:30:00 PM
BBIO,"Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells Fargo",6/7/2024 7:09:58 PM
BBIO,BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference,6/6/2024 1:30:00 PM
BBIO,The 3 Best Biotech Stocks to Buy in June 2024,6/5/2024 5:35:02 PM
BBIO,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insmed (INSM), Becton Dickinson (BDX) and BridgeBio Pharma (BBIO)",6/4/2024 6:20:11 PM
BBIO,"BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024",6/3/2024 10:01:00 PM
BBIO,"Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE)",5/31/2024 11:40:11 AM
BBIO,Buy Rating Affirmed for BridgeBio Pharma Amid Promising Acoramidis Clinical Results,5/30/2024 12:25:22 PM
BBIO,Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in...,5/29/2024 10:01:00 PM
BBIO,Wall Street Analysts Are Bullish on Top Healthcare Picks,5/28/2024 12:00:35 PM
BBIO,7 Biotech Stocks to Put on Your Breakthrough Radar,5/27/2024 4:32:15 PM
BBIO,"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo",5/25/2024 2:24:03 PM
BBIO,BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting,5/24/2024 1:30:00 PM
BBIO,Buy Rating Affirmed for BridgeBio Pharma on Strong Program Prospects and Competitive Edge,5/16/2024 9:55:21 AM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),5/15/2024 1:30:00 PM
BBIO,Evercore says biotech ‘winter is finally thawing’,5/14/2024 3:24:32 PM
BBIO,"BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment...",5/13/2024 1:30:00 PM
BBIO,Cantor picks 14 undervalued biotech stocks worth a second look,5/12/2024 3:00:00 PM
BBIO,"BBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024",5/3/2024 2:55:03 AM
BBIO,BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update,5/2/2024 1:30:00 PM
BBIO,Bank of America Securities Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO),4/30/2024 1:29:54 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),4/10/2024 1:30:00 PM
BBIO,Buy Rating Affirmed for BridgeBio Pharma on Acoramidis’ Positive ATTR-CM Trial Outcomes,4/8/2024 9:46:07 AM
BBIO,BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid...,4/7/2024 7:15:00 PM
BBIO,TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal,3/27/2024 10:25:28 AM
BBIO,Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments,3/25/2024 1:47:05 AM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),3/20/2024 12:30:00 PM
BBIO,"Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (PEPG), BridgeBio Pharma (BBIO) and Amedisys (AMED)",3/7/2024 4:20:19 AM
BBIO,BridgeBio prices $250M stock offering,3/6/2024 10:59:59 AM
BBIO,"Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Elevance Health (ELV)",3/5/2024 10:12:36 AM
BBIO,BridgeBio Pharma Announces Proposed Public Offering of Common Stock,3/4/2024 10:17:36 PM
BBIO,Optimistic Buy Rating for BridgeBio Pharma Amid Strong Market Position and Promising Treatment Pipeline,2/29/2024 11:26:51 AM
BBIO,Buy Rating Affirmed for BridgeBio Pharma on Strong Clinical Progress and Strategic Financial Positioning,2/26/2024 4:30:17 AM
BBIO,BridgeBio Pharma: Hold Rating Amidst Uncertainties in Product Launch and Market Dynamics,2/23/2024 12:29:44 PM
BBIO,Buy Rating Affirmed for BridgeBio Pharma Amidst Strong Acoramidis Prospects and Promising Pipeline Developments,2/22/2024 9:35:24 PM
BBIO,"Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday",2/15/2024 4:23:42 PM
BBIO,"Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), CVS Health (CVS) and BridgeBio Pharma (BBIO)",2/9/2024 6:20:43 AM
BBIO,"Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), BridgeBio Pharma (BBIO) and 23andMe Holding (ME)",2/8/2024 11:20:23 AM
BBIO,BridgeBio grants Japanese rights to Kyowa Kirin for dwarfism drug,2/7/2024 3:37:54 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),2/6/2024 1:30:00 PM
BBIO,BridgeBio Announces FDA Acceptance Of NDA For Acoramidis ,2/5/2024 2:50:15 PM
BBIO,"Analysts Are Bullish on Top Healthcare Stocks: Cigna (CI), BridgeBio Pharma (BBIO)",2/3/2024 5:51:07 PM
BBIO,BridgeBio Pharma Shares Positive Results From Phase 3 Study Of Acoramidis In ATTR-CM ,2/2/2024 1:59:26 PM
BBIO,"Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), Crispr Therapeutics AG (CRSP) and BridgeBio Pharma (BBIO)",1/31/2024 5:50:15 AM
BBIO,3 Groundbreaking Biotech Stocks to Invest in Now,1/29/2024 5:35:14 PM
BBIO,Analysts Have Conflicting Sentiments on These Healthcare Companies: BridgeBio Pharma (BBIO) and Abbott Labs (ABT),1/25/2024 2:31:52 AM
BBIO,7 Exciting Stocks Poised for Explosive Growth in Key Sectors,1/22/2024 11:30:00 AM
BBIO,"BridgeBio Climbs 4% On Strategic Investment From Blue Owl, CPP Investments ",1/18/2024 4:16:07 PM
BBIO,BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal...,1/10/2024 11:15:42 PM
BBIO,Optimistic Outlook: Buy Rating for BridgeBio Pharma with Promising Treatment Launches and Strategic Growth Drivers,1/9/2024 11:32:18 AM
BBIO,BridgeBio Pharma (BBIO) Receives a Buy from Goldman Sachs,1/8/2024 8:45:38 PM
BBIO,BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference,1/3/2024 10:30:00 PM
BBIO,"5 Top Healthcare Stocks to Buy Now, According to Analysts – December 2023",12/19/2023 6:49:53 AM
BBIO,3 Russell 2000 Stocks That Are About to Get Absolutely Crushed,12/18/2023 10:34:00 AM
BBIO,Buy Rating Affirmed for BridgeBio Pharma Amid Clinical Advancements and Positive Trial Outcomes,12/14/2023 1:55:22 AM
BBIO,"BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia",12/13/2023 1:30:00 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),12/8/2023 1:30:00 PM
BBIO,BridgeBio Pharma Announces NDA Submission For Acoramidis - Quick Facts ,12/5/2023 2:18:40 PM
BBIO,Promising Clinical Results Bolster Buy Rating for BridgeBio Pharma: An Analysis of Acoramidis Phase 3 Study,11/14/2023 7:15:58 AM
BBIO,Buy Rating for BridgeBio Pharma: Acoramidis’ Promising Performance and Potential Market Impact,11/13/2023 10:47:59 AM
BBIO,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BridgeBio Pharma (BBIO) and Boston Scientific (BSX)",11/12/2023 11:50:44 PM
BBIO,BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific...,11/9/2023 1:30:00 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),11/8/2023 1:30:00 PM
BBIO,Rare Disease Player BridgeBio Pharma's Upside Potential Is Significant According to Citi Analyst - Here's Why,11/7/2023 10:27:57 PM
BBIO,BridgeBio Pharma Receives Buy Rating Amid Promising Drug Pipeline Developments and Strong Financial Position,11/6/2023 6:02:46 AM
BBIO,"Analysts Have Conflicting Sentiments on These Healthcare Companies: American Well (AMWL), BridgeBio Pharma (BBIO) and Idexx Laboratories (IDXX)",11/2/2023 10:00:47 PM
BBIO,"Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023",10/24/2023 5:00:44 PM
BBIO,Wall Street Analysts Are Bullish on Top Healthcare Picks,10/19/2023 6:20:30 AM
BBIO,"Analysts Are Bullish on Top Healthcare Stocks: Terns Pharmaceuticals (TERN), BridgeBio Pharma (BBIO)",10/13/2023 8:40:25 AM
BBIO,BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),10/11/2023 1:30:00 PM
BBIO,BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1),10/10/2023 1:30:00 PM
BBIO,"BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle...",10/9/2023 1:30:00 PM
BBIO,Strategic Collaborations and Promising Outlook Boost BridgeBio Pharma: An Analysis of Buy Rating Factors,10/4/2023 9:08:10 AM
BBIO,"BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments",10/3/2023 1:30:00 PM
BBIO,Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty,9/28/2023 8:29:22 PM
BBIO,BridgeBio Pharma Announces $250 Mln PIPE Financing ,9/25/2023 3:10:41 PM
BBIO,BridgeBio Pharma (BBIO) Gets a Buy from Goldman Sachs,9/14/2023 3:15:06 AM
BBIO,Buy List Alert: 3 Pharma Stocks with Positive Trial Updates,9/13/2023 12:08:13 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),9/8/2023 1:30:00 PM
BBIO,BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference,9/7/2023 1:30:00 PM
BBIO,BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia,9/6/2023 1:30:00 PM
BBIO,Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Alkermes (ALKS),8/29/2023 12:31:38 PM
BBIO,"Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO), GE Healthcare Technologies Inc (GEHC) and Sotera Health (SHC)",8/28/2023 1:20:22 PM
BBIO,BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology...,8/27/2023 12:15:00 PM
BBIO,BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023,8/24/2023 10:01:00 PM
BBIO,"Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Teva Pharmaceutical (TEVA)",8/21/2023 9:30:26 AM
BBIO,4 Analysts Have This to Say About BridgeBio Pharma,8/14/2023 3:00:29 PM
BBIO,Goldman Sachs Sticks to Their Buy Rating for BridgeBio Pharma (BBIO),8/3/2023 4:35:09 PM
BBIO,BridgeBio Pharma (BBIO) Gets a Buy from Mizuho Securities,7/24/2023 9:45:09 AM
BBIO,"Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023",7/18/2023 5:00:54 PM
BBIO,Crude Oil Falls; GreenPower Motor Company Shares Spike Higher,7/17/2023 9:05:29 PM
BBIO,"CNDT, IBRX and EBIX are among after hour movers",7/14/2023 9:29:54 PM
BBIO,BridgeBio partnering with UAE healthcare provider on rare disease R&D,7/12/2023 9:18:41 PM
BBIO,Mizuho Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO),7/10/2023 4:35:28 PM
BBIO,"Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023",7/9/2023 10:15:18 PM
BBIO,Top 11 technical picks for the second half of 2023,7/7/2023 11:44:52 AM
BBIO,"BioMarin Presents ~20% Upside Amid Voxzogo's Success and Slow Roctavian Uptake, Analyst Says",7/5/2023 9:42:37 PM
BBIO,"Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), BridgeBio Pharma (BBIO) and Arcellx Inc (ACLX)",6/22/2023 10:02:07 AM
BBIO,"3 Best Stocks to Buy Now, 6/20/2023, According to Top Analysts",6/20/2023 10:56:08 AM
BBIO,BTIG Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO),6/19/2023 11:05:26 PM
BBIO,BridgeBio stock dips in wake of JP Morgan note on upcoming drug data,6/15/2023 4:47:29 PM
BBIO,Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Ascendis Pharma (ASND),6/7/2023 11:10:05 AM
BBIO,BridgeBio Pharma (BBIO) Gets a Buy from Bank of America Securities,5/30/2023 10:45:06 AM
BBIO,Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and NGM Biopharmaceuticals (NGM),5/11/2023 12:10:25 PM
BBIO,Mizuho Securities Remains a Buy on BridgeBio Pharma (BBIO),5/8/2023 10:35:28 AM
BBIO,"Catalyst Watch: CPI report, Icahn showdown and Spectrum Brands trial headline big week",5/5/2023 7:00:33 PM
BBIO,"BridgeBio Pharma GAAP EPS of -$0.92, revenue of $1.83M",5/4/2023 2:08:25 PM
BBIO,Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session,4/19/2023 7:04:49 PM
BBIO,What 5 Analyst Ratings Have To Say About BridgeBio Pharma,4/13/2023 6:00:51 PM
BBIO,Apellis Pharmaceuticals sees takeover interest from large pharma - Bloomberg,4/2/2023 8:32:28 PM
BBIO,Top 5 Best And Worst U.S. Industry ETFs In Q1 2023: AI and Bank Turmoil Shaped Stock Returns,3/31/2023 5:34:53 PM
BBIO,Mizuho Securities Sticks to Their Buy Rating for BridgeBio Pharma (BBIO),3/29/2023 7:25:04 PM
BBIO,SVB Securities Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO),3/28/2023 10:05:35 AM
BBIO,"First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session",3/27/2023 12:37:27 PM
BBIO,"IOVA, BBIO and IREN are among after hour movers",3/24/2023 9:28:03 PM
BBIO,"BridgeBio starts dosing in phase 1/2 trial of BBP-398, Opdivo combo for solid tumors",3/23/2023 12:29:24 PM
BBIO,BridgeBio Pharma (BBIO) Receives a Buy from Goldman Sachs,3/22/2023 1:15:11 PM
BBIO,"SPLK, HA and PRPL are among after hour movers",3/21/2023 8:57:51 PM
BBIO,BridgeBio Pharma Prices 8.823 Mln Public Offering At $17 Per Share ,3/8/2023 2:30:26 PM
BBIO,"Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday",3/7/2023 4:31:45 PM
BBIO,Why did BridgeBio Pharma stock surge today? Data on achondroplasia asset,3/6/2023 11:08:08 PM
BBIO,Bank of America Securities Remains a Buy on BridgeBio Pharma (BBIO),2/27/2023 11:15:09 AM
BBIO,BTIG Sticks to Their Buy Rating for BridgeBio Pharma (BBIO),2/24/2023 12:15:09 PM
BBIO,"BridgeBio Pharma GAAP EPS of -$0.92 misses by $0.07, revenue of $1.87M misses by $3.05M",2/23/2023 1:19:00 PM
BBIO,SVB Securities Sticks to Their Buy Rating for BridgeBio Pharma (BBIO),2/17/2023 3:05:40 PM
BBIO,Mizuho Securities Remains a Buy on BridgeBio Pharma (BBIO),2/15/2023 7:15:10 PM
BBIO,"Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023",2/6/2023 4:01:32 PM
BBIO,Mizuho Securities Remains a Buy on BridgeBio Pharma (BBIO),1/31/2023 7:55:10 PM
BBIO,SVB Securities Sticks to Their Buy Rating for BridgeBio Pharma (BBIO),1/23/2023 12:25:26 PM
BBIO,BridgeBio Pharma (BBIO) Receives a Buy from SVB Securities,1/6/2023 5:15:25 AM
BBIO,Mizuho Securities Remains a Buy on BridgeBio Pharma (BBIO),1/5/2023 10:55:08 AM
BBIO,Why BridgeBio Pharma Stock Is Shooting Higher,12/29/2022 7:19:57 PM
BBIO,BridgeBio starts phase 3 trial of encaleret for calcium disorder,12/22/2022 1:52:05 PM
BBIO,"LSPR, ALLK and JOAN among after hour movers",12/12/2022 10:17:13 PM
BBIO,"Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Guardant Health (GH) and BridgeBio Pharma (BBIO)",11/18/2022 12:11:53 PM
BBIO,BridgeBio Pharma to Participate in November Investor Events,11/9/2022 1:30:00 PM
BBIO,Mizuho Securities Sticks to Their Buy Rating for BridgeBio Pharma (BBIO),11/7/2022 7:05:08 PM
BBIO,"BridgeBio Pharma GAAP EPS of -$0.93 beats by $0.06, revenue of $0.34M misses by $4.33M",11/3/2022 1:17:27 PM
BBIO,Wall Street Analysts Are Bullish on Top Healthcare Picks,10/19/2022 5:21:18 AM
BBIO,BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative...,10/17/2022 6:30:00 PM
BBIO,BridgeBio Pharma Shares Preliminary Data From Gene Therapy Candidate In Ultra Rare Disorder,10/14/2022 4:01:02 PM
BBIO,BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society,10/13/2022 10:00:00 PM
BBIO,"BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status",10/11/2022 5:49:38 PM
BBIO,BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium,10/7/2022 1:30:00 PM
BBIO,"BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU",9/20/2022 1:38:25 PM
BBIO,"AMRS, ADPT and RETA are among after hour movers",9/19/2022 9:32:12 PM
BBIO,Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday,9/14/2022 9:58:12 AM
BBIO,"Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session",9/13/2022 6:32:59 PM
BBIO,BridgeBio Pharma to Participate in September Investor Events,9/6/2022 1:30:00 PM
BBIO,"BBIO, ADES and ALGM are among after hour movers",8/19/2022 9:26:33 PM
BBIO,BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off,8/18/2022 4:41:30 PM
BBIO,Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary,8/11/2022 12:23:03 AM
BBIO,"BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A",8/10/2022 1:30:00 PM
BBIO,"BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update",8/4/2022 1:30:00 PM
BBIO,"Applied DNA, Alnylam top healthcare gainers; BridgeBio, Horizon lead losers' pack",8/3/2022 2:05:33 PM
BBIO,Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday,7/27/2022 11:29:38 AM
BBIO,BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate,7/26/2022 2:38:35 PM
BBIO,EMA's Committee Says Nulibry Is Authorizable For Treating MoCD Type A: Sentynl Therapeutics ,7/25/2022 2:08:27 PM
BBIO,"BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub",7/21/2022 1:30:00 PM
BBIO,"BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone...",6/27/2022 1:30:00 PM
BBIO,"GH, FUV and CBAY among after hour movers.",6/24/2022 9:23:37 PM
BBIO,BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease,6/22/2022 7:43:08 PM
BBIO,"NVAX, SAFM and MCRB among after hour mover",6/21/2022 9:00:41 PM
BBIO,BridgeBio achieves positive phase 2 results for low calcium disorder drug encaleret,6/13/2022 2:02:45 PM
BBIO,"BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations",6/10/2022 1:30:00 PM
BBIO,BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference,6/9/2022 1:30:00 PM
BBIO,BridgeBio Pharma to Participate in June Investor Events,6/6/2022 1:30:00 PM
BBIO,BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate,5/26/2022 7:38:26 PM
BBIO,6 Analysts Have This to Say About BridgeBio Pharma,5/24/2022 11:39:27 PM
BBIO,BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder,5/20/2022 9:04:18 PM
BBIO,"BIOX, VECT and BBIO are among after hour movers",5/19/2022 9:54:02 PM
BBIO,BridgeBio Pharma to Participate in May Investor Events,5/17/2022 1:30:00 PM
BBIO,"The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product",5/13/2022 4:38:25 PM
BBIO,BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology,5/12/2022 3:48:34 PM
BBIO,BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference,5/10/2022 10:30:00 PM
BBIO,Where BridgeBio Pharma Stands With Analysts,5/6/2022 4:01:17 PM
BBIO,BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative',5/5/2022 9:37:46 PM
BBIO,BridgeBio Pharma chief strategy officer resigns amid layoffs - Endpoints News,4/27/2022 1:15:12 PM
BBIO,BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial,4/4/2022 3:17:21 PM
BBIO,BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM),4/3/2022 2:36:00 PM
BBIO,BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC)...,3/28/2022 1:30:00 PM
BBIO,"Pre-market Movers: MFH, ESOA, COOK, FSRD, ALLG… ",3/24/2022 12:57:24 PM
BBIO,"The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data",3/17/2022 12:53:34 PM
BBIO,What 6 Analyst Ratings Have To Say About BridgeBio Pharma,3/16/2022 6:03:03 PM
BBIO,"BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market",3/14/2022 4:27:03 PM
BBIO,"The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings",3/13/2022 10:37:36 PM
BBIO,"BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)",3/11/2022 1:30:00 PM
BBIO,Sentynl Buys BridgeBio Pharma's Fosdenopterin Rights In Genetic Disorder,3/8/2022 2:37:32 PM
BBIO,"Helsinn, BridgeBio Pharma Amend Infigratinib Pact For Oncology Indications",3/3/2022 5:36:25 PM
BBIO,BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update,2/24/2022 1:30:00 PM
BBIO,BridgeBio begins dosing of gene therapy in phase 1/2 trial for adrenal gland disorder,1/27/2022 1:33:44 PM
BBIO,"Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments",1/25/2022 3:00:00 PM
BBIO,"BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS...",1/13/2022 1:30:00 PM
BBIO,40 Biggest Movers From Friday,1/3/2022 10:46:50 AM
BBIO,The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week,1/2/2022 9:30:35 PM
BBIO,"NAIL, BBIO and LABD among weekly ETF movers",1/1/2022 10:29:00 PM
BBIO,21 Stocks Moving In Friday's Mid-Day Session,12/31/2021 6:02:35 PM
BBIO,Alnylam defended at BofA after selloff driven by BridgeBio’s trial setback,12/30/2021 1:22:27 PM
BBIO,45 Biggest Movers From Yesterday,12/29/2021 10:06:03 AM
BBIO,Why BridgeBio Pharma Shares Are Rising,12/28/2021 6:19:44 PM
BBIO,Mid-Afternoon Market Update: Dow Surges Over 200 Points; Microbot Medical Shares Spike Higher,12/27/2021 8:57:06 PM
BBIO,"The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year",12/26/2021 3:53:01 PM
BBIO,Why did BridgeBio Pharma stock go down today? Pending late-stage data,12/22/2021 7:44:44 PM
BBIO,63 Biggest Movers From Friday,12/20/2021 10:55:33 AM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),12/10/2021 1:30:00 PM
BBIO,Top stocks that may be tax loss selling bargains,12/4/2021 11:33:25 PM
BBIO,BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types,11/19/2021 1:30:00 PM
BBIO,BridgeBio Pharma nabs $750M in non-dilutive debt financing,11/18/2021 2:27:12 PM
BBIO,BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update,11/4/2021 12:30:00 PM
BBIO,BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease,11/3/2021 12:30:00 PM
BBIO,BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers,10/29/2021 1:30:00 PM
BBIO,"BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors",10/25/2021 1:30:00 PM
BBIO,LianBio files sets terms for $325M initial public offering,10/20/2021 9:38:25 PM
BBIO,"BridgeBio Pharma Announces Progress in its KRAS Portfolio, New Gene Therapy Programs, and Updates on Advancements Across its R&D Pipeline Targeting Genetic Diseases and Cancers",10/12/2021 1:30:00 PM
BBIO,"Catalyst Watch for next week: JPMorgan leads out big bank earnings; eyes on Plug Power, Alibaba and HubSpot",10/8/2021 6:30:13 PM
BBIO,"BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-sm...",10/7/2021 3:00:00 PM
BBIO,"BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021",10/6/2021 1:30:00 PM
BBIO,10 Biggest Price Target Changes For Monday,10/4/2021 2:31:31 PM
BBIO,BridgeBio Pharma Announces Updated Phase 2B Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants,10/1/2021 11:00:00 PM
BBIO,BBIO : FDA Grants Fast Track Designation For Therapy To Treat Limb-girdle Muscular Dystrophy Type 2i ,9/15/2021 1:45:31 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),9/8/2021 11:00:00 PM
BBIO,"BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors",8/18/2021 1:30:00 PM
BBIO,"BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update",8/5/2021 1:30:00 PM
BBIO,Notable earnings before Thursday's open,8/4/2021 2:00:37 PM
BBIO,"BridgeBio, Bristol Myers To Study BBP-398 In Combination With OPDIVO In Advanced Solid Tumors ",7/27/2021 1:57:04 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),7/12/2021 10:30:00 PM
BBIO,BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions,7/8/2021 1:30:00 PM
BBIO,7 Stocks to Buy Now if You’re Feeling Greedy While Others Are Fearful,6/24/2021 2:01:17 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),6/14/2021 10:35:00 PM
BBIO,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,6/1/2021 11:31:09 PM
BBIO,BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma,5/28/2021 8:30:00 PM
BBIO,"Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021",5/21/2021 4:08:34 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),5/14/2021 10:30:00 PM
BBIO,BridgeBio Pharma gains as name pitched long at Sohn Investment Conference,5/12/2021 4:57:43 PM
BBIO,"BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update",5/6/2021 1:30:00 PM
BBIO,"BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions",4/13/2021 1:45:00 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),4/6/2021 10:30:00 PM
BBIO,BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology,3/31/2021 1:30:00 PM
BBIO,BridgeBio posts early results from mid-stage encaleret genetic disorder study,3/22/2021 9:44:24 AM
BBIO,BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting,3/20/2021 4:00:00 PM
BBIO,Seeking Alpha Catalyst Watch,3/19/2021 7:30:46 PM
BBIO,"Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations",3/14/2021 1:14:58 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),3/2/2021 10:30:00 PM
BBIO,FDA OKs BridgeBio Pharma's Nulibry in severe neurologic damage,3/1/2021 9:56:09 AM
BBIO,"BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A",2/28/2021 2:00:00 PM
BBIO,"BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update",2/25/2021 1:30:00 PM
BBIO,BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting,2/24/2021 10:01:00 PM
BBIO,"The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More",2/20/2021 8:17:02 PM
BBIO,BridgeBio Pharma initiates dosing in mid-stage muscular dystrophy trial,2/19/2021 1:32:41 PM
BBIO,"The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed",2/12/2021 2:10:51 PM
BBIO,"BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common Stock",2/11/2021 10:09:37 PM
BBIO,"The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs",2/10/2021 1:34:43 PM
BBIO,"The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement",2/9/2021 2:10:28 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),2/5/2021 10:30:00 PM
BBIO,"BridgeBio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of BBP-681 for Venous, Lymphatic, and Venolymphatic Malformations",2/2/2021 1:30:00 PM
BBIO,"BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.",1/26/2021 2:30:00 PM
BBIO,BridgeBio Pharma to raise $400M in convertible debt,1/25/2021 1:14:53 PM
BBIO,"Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.",1/19/2021 10:01:00 PM
BBIO,"BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger",1/13/2021 10:30:00 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),1/6/2021 10:30:00 PM
BBIO,"BofA's biopharma picks into 2021 set to build with new launches, 'beatable' expectations",1/5/2021 11:37:37 PM
BBIO,Stocks That Hit 52-Week Highs On Monday,1/4/2021 6:58:02 PM
BBIO,Stocks That Hit 52-Week Highs On Wednesday,12/30/2020 4:21:57 PM
BBIO,"The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica",12/29/2020 2:09:37 PM
BBIO,Stocks That Hit 52-Week Highs On Monday,12/28/2020 4:22:20 PM
BBIO,Stocks That Hit 52-Week Highs On Thursday,12/24/2020 4:15:22 PM
BBIO,Stocks That Hit 52-Week Highs On Wednesday,12/23/2020 4:57:31 PM
BBIO,Stocks That Hit 52-Week Highs On Tuesday,12/22/2020 4:30:53 PM
BBIO,Stocks That Hit 52-Week Highs On Friday,12/18/2020 8:42:01 PM
BBIO,'Merger Monday' is back as economy continues to recover from COVID-19,12/14/2020 8:30:51 AM
BBIO,BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease,12/7/2020 2:30:00 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),12/4/2020 10:30:00 PM
BBIO,BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma,12/1/2020 1:30:00 PM
BBIO,Dosing underway in BridgeBio Pharma's BBP-398 early-stage study in solid tumor,11/13/2020 1:46:52 PM
BBIO,"BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update",11/5/2020 1:30:00 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),11/4/2020 10:30:00 PM
BBIO,Dosing underway in BridgeBio Pharma's BBP-589 study for rare genetic disorder,10/27/2020 12:41:22 PM
BBIO,"BridgeBio Pharma, Inc. and the University of Colorado Anschutz Medical Campus Collaborate to Advance Medicines for Genetically Driven Diseases",10/21/2020 1:30:10 PM
BBIO,Eidos Therapeutics downgraded by Citi analyst,10/7/2020 4:48:26 PM
BBIO,"GSK, AZN 1st To Use NVDA's Supercomputer, IOVA To Delay BLA Filing, YMAB Plunges, GLYC On Watch ",10/6/2020 8:39:29 AM
BBIO,BridgeBio To Buy All Remaining Stake In Eidos In $175 Mln Deal ,10/5/2020 2:13:01 PM
BBIO,BridgeBio Pharma and Affiliate Origin Biosciences Announces FDA Acceptance of its New Drug Application for Fosdenopterin for the Treatment of MoCD Type A,9/29/2020 1:30:10 PM
BBIO,"BridgeBio Pharma to Host Virtual R&D Day on September 29, 2020",9/22/2020 1:30:10 PM
BBIO,BridgeBio Pharma’s Calcilytix Therapeutics Initiates Phase 2 Study Of Encaleret For Autosomal Dominant Hypocalcemia Type 1 (ADH1) ,9/21/2020 1:30:10 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),9/3/2020 11:30:10 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),8/12/2020 10:30:10 PM
BBIO,"BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update",8/11/2020 1:40:10 PM
BBIO,Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma,7/28/2020 1:30:10 PM
BBIO,BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia,7/15/2020 1:30:10 PM
BBIO,BridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology’s 45th Annual Meeting,7/10/2020 1:30:10 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),7/6/2020 10:30:10 PM
BBIO,"BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors",6/24/2020 1:30:10 PM
BBIO,BridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases,6/18/2020 1:35:10 PM
BBIO,BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i),6/11/2020 1:00:10 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),6/5/2020 10:30:10 PM
BBIO,BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program,5/29/2020 1:30:10 PM
BBIO,BridgeBio Pharma’s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program and Announces New Leadership Appointments,5/13/2020 10:10:10 PM
BBIO,BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia,5/11/2020 1:30:10 PM
BBIO,"BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference",5/6/2020 10:30:10 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),5/5/2020 10:30:10 PM
BBIO,Leerink rolls out lineup of bullish calls in premarket analyst action,4/13/2020 11:51:46 AM
BBIO,"COST, AMC, KPTI and BIG among after-hours movers",4/8/2020 9:38:47 PM
BBIO,"CIM, TWO, APRN and TRTX among after-hours movers",4/6/2020 9:35:26 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),4/3/2020 10:30:00 PM
BBIO,BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations,3/12/2020 12:30:00 PM
BBIO,"BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes",3/5/2020 5:31:51 AM
BBIO,"BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes",3/4/2020 1:00:00 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),3/3/2020 10:30:00 PM
BBIO,BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress,3/2/2020 2:29:17 PM
BBIO,"BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board of Directors",2/24/2020 1:30:00 PM
BBIO,BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences,2/22/2020 1:25:36 AM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),2/6/2020 12:31:14 AM
BBIO,BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source,1/13/2020 1:30:00 PM
BBIO,BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity,1/10/2020 1:30:00 PM
BBIO,BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib...,1/6/2020 1:30:00 PM
BBIO,"BridgeBio Stock Up 60% So Far In Dec., IPO Lockup Period Expires Today ",12/24/2019 9:57:37 AM
BBIO,"BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference",12/19/2019 10:30:00 PM
BBIO,BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A,12/18/2019 1:30:10 PM
BBIO,"BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member",12/16/2019 1:30:00 PM
BBIO,"BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs",12/9/2019 1:30:00 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),12/6/2019 1:35:10 AM
BBIO,BridgeBio Pharma’s Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A,12/3/2019 1:30:00 PM
BBIO,BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),11/27/2019 10:30:10 PM
BBIO,BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress,11/7/2019 10:13:10 PM
BBIO,Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options,9/24/2019 1:00:00 PM
BBIO,BridgeBio Pharma’s Origin Biosciences Presents New Data on the Natural History of Molybdenum Cofactor Deficiency (MoCD) Type A at the Society of the Study of Inborn Errors of Metabolism (SSIEM)...,9/5/2019 10:00:00 PM
